Bambusa Therapeutics, Inc. (BBTX) Stock
NYSE · BBTX
Key stats
- Market cap
- $874.17M
- Price / Earnings ratio
- -21.6x
- EPS (TTM)
- -$9.39
- Volume
- Loading
- 52-week high
- $17.50
- 52-week low
- $13.60
Source: third-party data provider, as of November 13, 2026
Recent news
No recent news
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
174M115M57M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-39.3M
Net incomeEarnings
No data available
Source: third-party data provider
About Bambusa Therapeutics, Inc.
Bambusa Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation (“I&I”) and fundamentally improve patient quality of life.
Fundamentals
Valuation
Price-to-book value-11.96
Trading
Average volume529,484
Source: third-party data provider, as of November 13, 2026
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | +7.3 |
Compare stocks
Market cap
$874.17M
-
-
-
Price / Earnings ratio
-21.60
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
529,484
-
-
-
Earnings per share
$-9.39
-
-
-



